cagrisema phase 3 results 2025 semaglutide cagrilintide obesity Presenters to provide first look at data from REIMAGINE trials of cagrilintide/semaglutide for type 2 diabetes management Novo's CagriSema loses phase 3

The usual injection site is the lower abdomen near the stomach so it can enter the bloodstream quickly

What happened to body weight in the data after semaglutide was stopped

The company said it delivered a presentation at DDG 2026 in Berlin and was included in Germany's statutory health [Read More...] about Medtrum to bring 300U tubeless insulin patch pump to Germany Modular Medical inks IMO Health collab for insulin pump EHR integration Sean Whooley Abbott to launch Libre Duo dual sensor internationally in the fall, expects future reimbursement catalysts Sean Whooley Glucotrack combines with Lkahi Therapeutics to become CBGM subsidiary Sean Whooley In case you missed it Insulet, Calm partner on emotional well-being resources for diabetes ViCentra names new CFO, adds board member Dexcom picks up Health Canada nod for G7 15 Day Abbott gets FDA nod for longer length Esprit BTK drug-eluting scaffold FDA approves Sanofi anticancer treatment delivered through Enable Injections on-body device ViCentra Kaleido with G7, DBLG2 algorithm now available in Germany Vivani, Novo Nordisk partner to evaluate long-term semaglutide implant Insulet launches Omnipod 5, Omnipod Discover in Spain Trinity Biotech reports positive clinical findings for next-gen CGM Tandem Diabetes Care launches t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in new geographies BD names new president of Pharmacy Automation biz Terrestrial Bio doses first patients in GLP-1 patch trial MiniMed adds Alcon CEO, Medtronic exec to board of directors Anodyne picks up $12.6M to advance once-weekly GLP-1 patch Modular Medical launches Pivot tubeless insulin patch pump Clinical Trials Vivani, Novo Nordisk partner to evaluate long-term semaglutide implant Vivani Medical (Nasdaq:VANI) today announced a new agreement with Novo Nordisk to evaluate the NPM-139 long-term semaglutide implant

Certain anti-obesity drugs, including selective serotonin reuptake inhibitors and naltrexone/bupropion combinations, have been linked to adverse psychological outcomes such as mood alterations and suicidal ideation [69]